Indications
Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
Composition
- Active substance
- asenapine maleate
- International name (INN)
- asenapine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Sycrest
- Active substance
- asenapine maleate
- ATC code
- N05AH05
- Group
- Nervous system
- Therapeutic area
- Bipolar Disorder
- Marketing authorisation holder
- Organon N.V.
- Status
- Authorised
- EU authorisation